BANK OF GENES

BETTER, FASTER, CHEAPER One application of BGI's comprehensive sequencing and bioinformatics services is the NIFTY test (Non-Invasive Fetal TrisomY test), which was the first non-invasive prenatal testing solution to enter clinical trial in 2010 for detecting likely birth diseases such as Down Syndrome. "With the introduction [ofthe] two-child policy in China many ofthe pregnant women-to-be [are] older than 35, which means a higher risk, for example, ofthe Down Syndrome," Chen said, predicting even more red-hot growth for the company's NIFTY testing services. According to DPI Research, China's market for non-invasive prenatal testing is likely to reach more than $1.7 Billion by 2024. FA "IF THERE IS A COMPANY THAT CAN ESTABLISH A PARADIGM IN CHINA TO SHOWCASE PRIVATE SECTOR'S POTENTIAL IN PUBLIC-SECTOR BUSINESSES, IT'S GOT TO BE BGI" -Chen Yiqing, BGI Genomics $2.7b Cost of sequencing a whole human genome in 2003